Contact Us

At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.

1 min read

New Research from Flow Assays for Platelet Biology and Vascular Pharmacology Studies

Dr. Giordano Pula, PhD, Group Leader for Haemostasis and Thrombosis, University Medical Center Eppendorf, University of Hamburg


New Research from Flow Assays for Platelet Biology and Vascular Pharmacology Studies

After a short introduction on the physio-pathological roles of platelets and the importance of their cell adhesion mechanisms for human health, I will present data from our most recent studies on the redox-dependent regulation of platelet activity and the role of NADPH oxidases (NOXs) in thrombosis using the BioFlux system. We discovered agonist specificity of the activation of NADPH oxidases during platelet activation, with NOX1 prominently activated by collagen, while thrombin and other agonists activate both NOX1 and NOX2. The inhibition of NOX1 has strong antiplatelet effects in vitro. Collagen-dependent thrombus formation under flow is abolished by NOX1 inhibition in human platelets or genetic deletion in mouse platelets. Importantly, although thrombosis tested in vivo in carotid occlusion and pulmonary embolism assays is severely impaired by NOX1 inhibition, haemostasis remains unaffected. This suggests the possibility to design NOX1-specific drugs to be used as antithrombotics with no bleeding side effects. This work suggests how the modelling of thrombus formation by flow assays in vitro may find important applications in vascular biology and drug discovery.